NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free AVBP Stock Alerts $15.44 -0.10 (-0.64%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$15.36▼$16.4850-Day Range$15.30▼$22.7552-Week Range$14.35▼$25.95Volume53,529 shsAverage Volume155,197 shsMarket Capitalization$517.09 millionP/E RatioN/ADividend YieldN/APrice Target$30.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get ArriVent BioPharma alerts: Email Address ArriVent BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside98.6% Upside$30.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 4 Articles This WeekInsider TradingAcquiring Shares$18 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.16) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector703rd out of 914 stocksPharmaceutical Preparations Industry320th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AVBP. Previous Next 0.0 Dividend Strength Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVBP. Previous Next 1.1 News and Social Media Coverage News SentimentArriVent BioPharma has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ArriVent BioPharma this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,999,982.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ArriVent BioPharma are expected to grow in the coming year, from ($3.16) to ($2.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About ArriVent BioPharma Stock (NASDAQ:AVBP)ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Read More AVBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVBP Stock News HeadlinesApril 22, 2024 | globenewswire.comArriVent Appoints Kristine Peterson to its Board of DirectorsApril 21, 2024 | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Shares Up 4.9%April 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 1, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma Highlighting Furmonertinib’s Potential in NSCLC Treatment LandscapeMarch 29, 2024 | finanznachrichten.deArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2023 Financial ResultsMarch 28, 2024 | businesswire.comInnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor FurmonertinibMarch 28, 2024 | msn.comArriVent BioPharma reports FY resultsMarch 28, 2024 | globenewswire.comArriVent BioPharma Reports Full Year 2023 Financial ResultsApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 6, 2024 | uk.investing.comArrivent Biopharma Inc (AVBP)March 5, 2024 | markets.businessinsider.comBuy Rating on ArriVent BioPharma: Advancing NSCLC Treatment with Promising Furmonertinib ProspectsSee More Headlines Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)6/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CUSIPN/A CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$30.67 High Stock Price Target$35.00 Low Stock Price Target$27.00 Potential Upside/Downside+98.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.76 Quick Ratio13.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.79) per share Price / Book-3.22Miscellaneous Outstanding Shares33,490,000Free FloatN/AMarket Cap$517.09 million OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Zhengbin Yao Ph.D. (Age 58)Co-Founder, Chairman, President & CEO Comp: $791.09kDr. Stuart Lutzker M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Director Comp: $709.43kMs. Robin LaChapelle M.A. (Age 51)Co-Founder & COO Comp: $586.45kMr. Winston Kung M.B.A. (Age 48)CFO & Treasurer Ms. Yang Wang Ph.D.Chief Technology OfficerMr. James Paul Kastenmayer J.D. (Age 52)Ph.D., General Counsel & Secretary Dr. Dandan Dong (Age 39)Chief Business Officer Ms. Meghna ChowdarySenior Vice President of Commercial StrategyMore ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVCureVacNASDAQ:CVACORIC PharmaceuticalsNASDAQ:ORICPhathom PharmaceuticalsNASDAQ:PHATAnaptysBioNASDAQ:ANABView All CompetitorsInsidersHillhouse Investment ManagemenBought 555,555 shares on 1/30/2024Total: $10.00 M ($18.00/share)Orbimed Advisors LlcBought 444,444 shares on 1/30/2024Total: $8.00 M ($18.00/share)View All Insider Transactions AVBP Stock Analysis - Frequently Asked Questions Should I buy or sell ArriVent BioPharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArriVent BioPharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVBP shares. View AVBP analyst ratings or view top-rated stocks. What is ArriVent BioPharma's stock price target for 2024? 3 analysts have issued 12 month price targets for ArriVent BioPharma's stock. Their AVBP share price targets range from $27.00 to $35.00. On average, they predict the company's stock price to reach $30.67 in the next year. This suggests a possible upside of 98.6% from the stock's current price. View analysts price targets for AVBP or view top-rated stocks among Wall Street analysts. How have AVBP shares performed in 2024? ArriVent BioPharma's stock was trading at $20.00 at the start of the year. Since then, AVBP shares have decreased by 22.8% and is now trading at $15.44. View the best growth stocks for 2024 here. When is ArriVent BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our AVBP earnings forecast. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share. When did the company's quiet period expire? ArriVent BioPharma's quiet period expired on Wednesday, March 6th. ArriVent BioPharma had issued 9,722,222 shares in its IPO on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVBP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market InsidersThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
